Patient-derived Xenograft Core Facility (PDXCF)

项目摘要/摘要 患者衍生的异种移植物核心设备(PDXCF)是最近建立和发展起来的 对免疫缺陷(NSG)小鼠繁殖群体的机构投资，以及癌症的努力 研究调查员，致力于开发易于处理的人类肿瘤动物模型。世界银行的使命是 PDXCF将为以下对象生成与异种人类癌症非常相似的尖端癌症模型 肿瘤微环境(TME)生物医学研究卓越中心(COBRE)的研究人员 当务之急，并对整个校园的调查人员扩大这一资源的整体影响。这个核心将 加强对TME的了解，促进癌症新疗法的开发，并改进 临床前药物评价。为调查人员提供的服务将被量身定做，以最大限度地满足研究需求 TME Cobre的项目。PDXCF核心将提供以下服务：1)组织移植 研究人员为生产新的PDX品系提供的样本；2)已建立的PDX品系的繁殖；以及3) 协助提交IRB和IACUC方案/修正案。通过扩大研究基础设施， 这一核心设施使研究人员能够更有竞争力地获得外部资金，建立和发展 生产性研究计划，并改进将基础科学转化为治疗应用的过程。 建议书描述了该设施提供的服务及其管理计划、收费结构、 确定优先顺序、质量保证计划和战略，以在项目的整个生命周期及以后维持设施。 WVU PDXCF的具体目标是：1)促进翻译研究和最佳生产力 项目负责人(PLS)；2)支持和开发最初TME Cobre之外的应用程序的核心 项目负责人，并支持WVUCI和其他WV机构发展奖(IDEA)的活动 具有共同总体目标的计划，即通过创新的翻译 科学。重要的是，这一核心设施将增加来自患者群体的肿瘤细胞的可用性 在目前可用的商业PDX来源中代表性不足。

PROJECT SUMMARY/ABSTRACT The Patient-Derived Xenograft Core Facility (PDXCF) has been recently established and evolved from institutional investments in a breeding colony of immunodeficient (NSG) mice, and the efforts of a cancer research investigator who worked to develop tractable animal models of human tumors. The mission of the PDXCF is to generate cutting edge cancer models that closely resemble heterogeneous human cancers for investigators in the Tumor Microenvironment (TME) Center of Biomedical Research Excellence (CoBRE) as the top priority, and to investigators across the campus to broaden overall impact of this resource. This core will enable enhanced understanding of the TME, facilitate development of novel cancer therapeutics, and improve pre-clinical drug evaluation. Services offered to investigators will be tailored to best fit the needs of research projects in the TME CoBRE. The PDXCF core will provide the following services: 1) transplantation of tissue samples provided by investigators to produce new PDX lines; 2) propagation of established PDX lines; and 3) assistance with submission of IRB and IACUC protocols/amendments. By expanding the research infrastructure, this core facility enables researchers to be more competitive for extramural funding, establish and grow productive research programs, and improve the process of translating basic science to therapeutic application. The proposal describes services provided by the facility along with its management plan, fee structure, prioritization, quality assurance plan, and strategies to sustain the facility over the life of the project and beyond. The Specific Aims of the WVU PDXCF are: 1) to advance the translational research and optimal productivity of the Project Leaders (PLs); 2) to support and develop the core for applications outside the initial TME CoBRE project leaders, and to support the activities of the WVUCI and other WV Institutional Development Award (IDeA) programs that share the overarching goal to reduce cancer health disparities through innovative translational science. Importantly, this core facility will increase the availability of tumor cells from a patient population that is underrepresented in currently available commercial PDX sources.